AZNCF News and Press, AstraZeneca Plc From 07/02/20

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...

A lot of small molecule anticancer drugs have significant downsides due to poor solubility (requiring detergent additives that are toxic) and serious side effects (due to the need for high dosing to make an effective dose). Starpharma's (OCTQX: OTCQX:SPHRY ) dendrimer delivery technology ((D...

On June 6, I warned of growing risk of a 5% pullback because the percentage of stocks trading more than 5% above their 200-day moving average had significantly increased to nearly 40%. A 7% retreat in the SPDR S&P 500 Trust ETF ( SPY ) between June 8 and June 11 has normalized this indic...

Quick Take Greenwich LifeSciences ( GLSI ) has filed to raise $23.5 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing an immunotherapy designed to prevent the recurrence of breast cancer. GLSI is preparing to enter Phase 3 trials ...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

AstraZeneca ( AZN ) is a company that many are optimistic about. Indeed, they have good reason to be. It trades at a higher multiple due to the high probability that the company will get an earnings bump from expansion of indications of current products like Tagrisso as well as other upcoming ...

Syndax Pharmaceuticals ( SNDX ) had recently failed a phase 3 study using its drug entinostat plus exemestane, to treat patients with advanced HR+/HER2- breast cancer who had progressed on a non-steroidal aromatase inhibitor. This study failed to meet the primary endpoint of overall survival...

Quick Take Vaxcyte ( PCVX ) intends to raise $210 million in an IPO of its ordinary shares, per an amended registration statement . The company is developing a family of vaccines for pneumococcal and other global markets. PCVX is a very early stage, preclinical vaccine researcher and th...

The following slide deck was published by AstraZeneca PLC in conjunction with this Read more ...

Have you ever found yourself saying a stock is too expensive because it's made a big move in a short period of time? Or that a stock is too cheap to ignore because its price has fallen sharply? Anchoring bias, or the tendency to fixate on a past price when considering a new investment idea, ca...